A meta-analysis of 3 trials with 922 patients found once-weekly semaglutide produced 4.55 kg more weight loss and significantly better blood sugar control than once-daily liraglutide, with comparable safety.
4.55 kg more weight lossOnce-weekly semaglutide vs once-daily liraglutide across 3 randomized controlled trials in type 2 diabetes
What the researchers found
Across 3 RCTs with 922 patients, once-weekly semaglutide versus once-daily liraglutide produced: significantly greater weight loss (WMD -4.55 kg, 95% CI -6.43 to -2.67, p<0.01), greater HbA1c reduction (WMD -0.46%, 95% CI -0.84 to -0.08, p=0.02), and greater fasting plasma glucose reduction (WMD -1.23 mmol/L, 95% CI -1.51 to -0.95, p<0.01). Safety was comparable: severe adverse events (OR 1.66, p=0.38) and GI adverse events (OR 1.84, p=0.14) did not significantly differ between groups.
Why it matters
Semaglutide and liraglutide are both widely prescribed GLP-1 drugs, but many patients and clinicians wonder which is better. This meta-analysis provides clear evidence that semaglutide delivers superior weight and glycemic outcomes with the convenience of weekly dosing, helping inform one of the most common prescribing decisions in diabetes and obesity care.
How the study worked
Systematic review and meta-analysis of randomized controlled trials from Cochrane Library, PubMed, and ScienceDirect through July 2024. Three RCTs comparing once-weekly semaglutide to once-daily liraglutide were included. Analysis used R version 4.4.1 with a random effects model to account for between-study variability.
What this study cannot tell us
Only 3 RCTs with 922 total patients were available, which is a relatively small evidence base for a meta-analysis. The specific semaglutide and liraglutide doses compared may have varied across trials. A random effects model was appropriately used, but heterogeneity across studies may still affect results. The analysis focused on diabetes patients and may not fully generalize to weight management in non-diabetic populations.
How to read the evidence
This is a meta-analysis of 3 randomized controlled trials — a strong study design, but the small number of included trials and modest total sample size (922) moderate the overall evidence strength.
When this study was published
Published in 2025 with data through July 2024, this meta-analysis represents the current evidence base for this commonly debated clinical comparison.
The bigger picture
The GLP-1 receptor agonist market has exploded with options, and head-to-head comparisons are essential for evidence-based prescribing. Semaglutide's superiority over liraglutide — the previous market leader — on both efficacy and convenience helps explain its rapid market dominance and supports its position as a preferred first-line GLP-1 option.
Questions still open
- How does higher-dose semaglutide (2.4 mg for weight management) compare to liraglutide 3.0 mg (the approved weight-loss dose)?
- Does semaglutide's superiority persist with longer follow-up beyond the trial durations?
- Are there specific patient subgroups where liraglutide might still be preferred over semaglutide?
Common questions
Is semaglutide better than liraglutide for everyone?
Does weekly dosing work as well as daily dosing?
Read the original research
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
Clinical and translational science, 18(2), e70127
Citation
Hashmi, Tallal Mushtaq; Ahmed, Mushood; Haider, Ali; Naseem, Salman; Jafar, Uzair; Hussain, Munir; Iqbal, Javed; Ali, Waqar; Ahmed, Raheel. (2025). Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.. Clinical and translational science, 18(2), e70127. https://doi.org/10.1111/cts.70127